Macrocyclic IRAK-4 Inhibitors With Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IRAK-4 inhibitors are inadequate for effectively treating autoimmune diseases and inflammatory disorders, and there is a need for novel compounds with superior IRAK-4 inhibitory activity.
Innovation Solution
Development of novel macrocyclic compounds represented by specific chemical formulas with varying substituents and functional groups, which exhibit strong IRAK-4 inhibitory activity and selective kinase inhibition, particularly targeting FLT3, while showing low genetic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current IRAK-4 inhibitors are used, then some inhibitory activity is achieved, but the effectiveness for treating autoimmune diseases and inflammatory disorders is inadequate
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of IRAK-4 inhibitors through macrocyclization and introducing specific substituents (R1-R6 groups) to enhance inhibitory activity. The macrocyclic structure and varied substituent patterns optimize the compound's interaction with IRAK-4, significantly improving therapeutic effectiveness for autoimmune diseases and inflammatory disorders compared to previous inhibitors.
Solution Approach 2:
The patent employs composite material principles by creating complex macrocyclic compounds that integrate multiple functional groups and structural elements. These composite molecular structures combine various chemical moieties (including aromatic rings, heterocyclic groups, and alkyl chains) to achieve superior IRAK-4 inhibition and therapeutic effect.
2Adaptability or versatility
If broad kinase inhibition is achieved, then multiple disease pathways are targeted, but selectivity is reduced leading to increased genetic toxicity
Solution Approach 1:
The patent applies local quality by designing macrocyclic compounds with specific local structural features (R1-R6 substituents) that provide selective interaction with IRAK-4 while avoiding off-target kinase inhibition. The localized chemical modifications enhance binding affinity for IRAK-4's unique structural features, achieving high selectivity and reducing genetic toxicity associated with broad kinase inhibition.
Solution Approach 2:
The patent converts the potential harm of broad kinase inhibition into benefit by designing macrocyclic structures that selectively target IRAK-4. The macrocyclic framework, while capable of interacting with multiple kinases, is optimized through specific substituents to preferentially bind IRAK-4, thereby converting the risk of off-target effects into selective therapeutic action with reduced genetic toxicity.
Data Source
AI summary
A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.